NeuroSense Therapeutics Ltd. Adjustments For Fair Value Gains Losses
NeuroSense Therapeutics Ltd. (NRSN) reported Adjustments For Fair Value Gains Losses of -$4.04 million for the 12-month period ending 2023-12-31, per its 20-F filed 2024-04-04.
Discontinued › Income Statement › Other Income
ifrs-full:AdjustmentsForFairValueGainsLosses · last filed 2024-04-04
| Period end | Adjustments For Fair Value Gains Losses 6 month | Adjustments For Fair Value Gains Losses 12 month |
|---|---|---|
| 2023-12-31 | -$4.04M 20-F · filed 2024-04-04 | |
| 2023-06-30 | -$73.00K 6-K · filed 2023-08-16 | |
| 2022-12-31 | -$1.17M 20-F · filed 2024-04-04 | |
| 2022-06-30 | -$693.00K 6-K · filed 2023-08-16 | |
| 2021-12-31 | -$2.73M 20-F · filed 2024-04-04 |